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Background and aims: A number of agents have been evaluated in clinical trials to reduce the risk of
postoperative recurrence in Crohn’s disease (CD). The aim of this study was to compare the efﬁcacy of 5-
aminosalicylates, immunomodulators and biologics for postoperative prophylaxis of CD recurrence by
using a network meta-analytical approach.
Methods: PubMed, Embase, and Cochrane Library were searched (update to November 2013) to identify
randomized placebo-controlled, or head-to-head trials among the three drug classes for prevention of
postoperative CD relapse. The primary endpoint for efﬁcacy was endoscopic recurrence, and the sec-
ondary outcomes were clinical recurrence and adverse events. We conducted a Bayesian network meta-
analysis with a mixed treatment comparisons to combine both direct and indirect evidences.
Results: Fifteen trials involving 1507 patients were included in this analysis. Biological agents were
associated with a large and signiﬁcant reduction of both endoscopic and clinical recurrence compared
with placebo, 5-aminosalicylates, or immunomodulators. Immunomodulators showed greater efﬁcacy in
terms of endoscopic and clinical recurrence prophylaxis compared with 5-aminosalicylates or placebo,
but with higher incidence of adverse events. 5-aminosalicylates were superior to placebo for prevention
of clinical recurrence, without increasing the rate of side effect.
Conclusions: 5-aminosalicylates, immunomodulators, and biologics are more efﬁcacious than placebo for
postoperative CD prevention. Biologics are found to be the most effective medications to prevent CD
recurrence.
 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Despite evolving medical management of Crohn’s disease (CD),
approximately 70e80% of patients require intestinal surgery for
medically refractory disease or complications during their disease
course [1,2]. However, surgery does not cure the disease, and
postoperative recurrence remains a signiﬁcant concern in CD pa-
tients. Population-based studies reported the clinical recurrence
rates ranging from 28% to 45% at ﬁve years and from 36% to 61% at
ten years, respectively [3].osalicylates; TNF, tumor ne-
CrI, credible interval.
).
by Elsevier Ltd. All rights reservedEfforts have been made in the preoperative, intraoperative and
postoperative stages for prophylaxis of CD recurrence after surgery.
First, doctors attempted to identify risk proﬁle in a patient to pre-
dict the probability of relapse. To date, only tobacco smoking is a
strong and modiﬁable risk factor [3,4]. Secondly, surgeons tried to
improve surgical parameters to decrease the recurrence rate.
Nevertheless, there is no single surgery-speciﬁc factor that has
been conclusively associated with postoperative CD recurrence
[3,5]. Finally, medical intervention following surgical resection has
been considered as best option to prevent postoperative recurrence
[6]. Various medications haven been evaluated in this setting, but
no consensus on the optimal algorithm has been reached until now
[7,8].
Agents that have been investigated include 5-aminosalicylates
(5-ASA), thiopurines, antibiotics, probiotics, corticosteroids,
interleukin-10, tumor necrosis factor (TNF) inhibitors, etc. [2,7] 5-
ASA has modest beneﬁt in preventing relapse of CD with.
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mesalamine, not for sulfasalazine [9]. Thiopurines are more effec-
tive than placebo or mesalamine in preventing postoperative
recurrence of CD, but at the expense of a high rate of adverse events
leading to drug withdrawal [10]. Nitroimidazole antibiotics can
reduce the risk of clinical and endoscopic recurrence in short-term
compared with placebo, but the intolerable side-effects limit their
use of high doses in clinical practice. [11] Available evidences have
failed to show any efﬁcacy for postoperative prophylaxis of CD by
using probiotics [11,12], budesonide [13,14], and interleukin-10
[15]. Although the data are limited, the use of TNF inhibitors in
the postoperative setting to prevent CD recurrence has shown great
promise. [4,6] They seemed to dramatically reduce postoperative
recurrence in selected CD patients [16]. However, the role of bio-
logic therapy in the average-risk population and whether they are
superior to other effective agents are still unclear.
The aim of this studywas to investigate the comparative efﬁcacy
of 5-ASA (onlymesalamine), immunomodulators (azathioprine and
6-mercaptopurine) and biologics (inﬂiximab and adalimumab) for
the prevention of postoperative recurrence in CD. Because the
number of randomized trials directly comparing these drug classes
is limited, we performed a network meta-analysis to integrate both
direct and indirect evidences across multiple trials. Network meta-
analysis allows a uniﬁed, coherent analysis of all randomized
controlled trials that compare these agents head to head or with
placebo [17].
2. Materials and methods
2.1. Search strategy and trial identiﬁcation
We did a bibliographic search in the databases of PubMed,
Embase, and Cochrane Central Register of Controlled Trials to
identify randomized, placebo-controlled, and head-to-head studies
reporting the effect of mesalamine, azathioprine, 6-
mercaptopurine, inﬂiximab, and adalimumab on postoperative
prophylaxis of CD recurrence. The PubMed search strategy is
detailed in Appendix 1. Reference lists from systematic reviews and
primary studies were hand-searched for additional relevant pub-
lications. The search was last updated on 15 November, 2013.
Studies were included if theymet all of the following criteria: (1)
randomized controlled design; (2) either placebo-controlled or
positive-controlled among the three drug classes; (3) examined
prophylactic treatment for postoperative CD; (4) had similar
baseline characteristics in each arm to ensure effective random
assignment; and (5) were published in English. If trial data sources
overlapped in multiple reports, the study published as full-text
with more sufﬁcient information was included.
2.2. Data extraction, outcome measures and quality evaluation
Study selection and data extraction were analyzed by two in-
dependent investigators (Z.Y. and Q.W.); disagreements were
resolved by consulting a third investigator (D.F.). We extracted data
on the ﬁrst author’s name, year of trial publication, publication
type, country of origin, number of centers involving in the trial,
drug regimen in each intervention group, number of participants,
and follow-up duration. Additional data about patient character-
istics extracted when available included age, gender, proportion of
current smokers, proportion of patients previously receiving in-
testinal surgery, disease duration, proportion of patients with
penetrating behavior and perianal disease, and location of disease.
The prespeciﬁed primary outcome of interest was endoscopic
recurrence according to the criteria of Rutgeerts. The Rutgeerts
score not only serves as real-time assessment for endoscopicrecurrence, but also provides prognostic information for further
clinical recurrence [5]. We deﬁned the score i2 or greater as
endoscopic recurrence, i3 or greater as severe endoscopic recur-
rence. Secondary outcomes were clinical recurrence and adverse
events. The deﬁnition of clinical recurrence in each study was
summarized in Supplemental Table 1. From each study, we
extracted incident number and rate of relapse for each intervention
group.
Two independent reviewers (Z.Y. and X.Y.) evaluated the quality
of individual studies on the basis of Jadad scale, which is a ﬁve-
point score system in three aspects of randomization, blinding,
and withdrawals and dropouts [18].2.3. Statistical analysis
To best summarize the totality of available evidence, we con-
ducted direct and network meta-analyses comparing 5-ASA, im-
munomodulators, biologics, and placebo. Whenever possible we
used results from intention-to-treat analysis.
In conventional direct meta-analysis, two or more studies that
compared two interventions of interest were statistically com-
bined. We calculated the pooled odds ratio (OR) with 95% conﬁ-
dence interval (CI) by using a random-effects model. We used the
Cochrane’s Q test to assess heterogeneity of the treatment effect
and considered a threshold P value less than 0.1 as statistically
signiﬁcant. We also used I2 statistic to evaluate the magnitude of
the heterogeneity among studies. A value greater than 50% in-
dicates substantial heterogeneity. We used the Egger regression
test to examine potential publication bias and deﬁned its signiﬁ-
cance as a P value less than 0.05. The direct meta-analysis was done
by using the software STATA (Version 12.0; Stata Corporation,
College Station, Texas, USA).
Given the limited number of studies for direct comparisons, we
used a network meta-analytical approach to simultaneously
combine both direct and indirect comparisons between studies
[19]. Network meta-analysis was conducted by using a Bayesian
Markov-chain Monte Carlo method and ﬁtted in the software
ADDIS (Version 1.16.3; Drug Information Systems). Analytical re-
sults are presented as ORs with 95% credible intervals (CrIs). In the
presence of minimally informative priors, CrI can be interpreted
like conventional CI [17]. Rankings regarding treatment efﬁcacy of
the three drug classes and placebo were originally derived from
Monte Carlo simulations and presented as the probability of pos-
sessing a speciﬁc ranking, in which the probabilities of different
rankings of the same treatment were summed to 100% [20]. Pooled
results were considered statistically signiﬁcant for P< 0.05 or if the
95% CI (CrI) did not contain the value 1.3. Results
3.1. Search results
A total of 292 citations were identiﬁed through electronic
searches. Of these, 273 were excluded after title and/or abstract
screening, leaving 19 studies for further evaluation. One study
published as meeting abstract was duplicate with a full-length
publication thereafter [21]. Two abstracts reported long follow-up
survey of the previous trials [22,23]; but we could not access suf-
ﬁcient data on the primary or secondary outcome of interest.
Another two studies were excluded due to the absence of an
adequate control [24,25]. So the remaining 14 studies fulﬁlled our
inclusion criteria [21e23,26e36]. One additional relevant study
was identiﬁed through a manual search of the reference section of
identiﬁed articles and former meta-analyses [37]. Finally, 15
Table 1
Study characteristics and number of events for each outcome.
First author Year Publication
type
Country No. of
centers
Drug regimen
Ardizzone
[26]
2004 Full-text Italy 1 AZA: 2 mg/kg/day
Mesalamine: 3 g/day
Armuzzi [21] 2013 Full-text Italy 1 IFX: 5 mg/kg, standar
schedule
AZA: 2.5 mg/kg/day
Brignola [27] 1995 Full-text Italy 8 Mesalamine: 3 g/day
Placebo
Caprilli [28] 1994 Full-text Italy 15 Mesalamine: 2.4 g/da
Placebo
D’Haens [29] 2008 Full-text Belgium 2 AZA: 100 mg/day
if < 60 kg or 150 mg/
if > 60 kga
Placeboa
Florent [30] 1996 Full-text France, Belgium 12 Mesalamine: 3 g/day
Placebo
Hanauer [31] 2004 Full-text USA 5 6-MP: 50 mg/day
Mesalamine: 3 g/day
Placebo
Herfarth [32] 2006 Full-text Germany, Czech NA AZA: 2e2.5 mg/kg/da
Mesalamine: 4 g/day
Lochs [33] 2000 Full-text Austria, Denmark,
Germany, Norway,
Sweden,
Switzerland
29 Mesalamine: 4 g/day
Placebo
McLeod [34] 1995 Full-text Canada, USA 7 Mesalamine: 3 g/day
Placebo
Regueiro [22] 2009 Full-text USA 1 IFX: 5 mg/kg, standar
schedule
Placebo
Reinisch [23] 2010 Full-text Austria, Czech,
Germany, Israel
21 AZA: 2e2.5 mg/kg/da
Mesalamine: 4 g/day
Savarino [35] 2013 Full-text Italy NA ADA: 160/80/40 mg,
standard schedule
AZA: 2 mg/kg/day
Mesalamine: 3 g/day
Sutherland
[37]
1997 Full-text Canada 31 Mesalamine: 3 g/day
Placebo
Yoshida [36] 2012 Full-text Japan 1 IFX: 5 mg/kg/8-weekb
Placebob
NA, data not available; AZA, azathioprine; IFX, inﬂiximab; 6-MP, 6-mercaptopurine; ADA
a All patients in both arms received metronidazole 750 mg/day for 3 months. Patients
b A few patients in both arms received elemental diet less than 1200 kcal/day and me
between inﬂiximab and control groups with regard to these medications.
Fig. 1. Flow diagram for study selection.
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included in this meta-analysis (Fig. 1).
3.2. Study and patient characteristics
Table 1 summarizes the included randomized trials. The trials
were published from 1994 to 2013 and varied in sample size (range,
22e318; median, 81). Only one study was performed in East Asia,
whereas the others in Western countries. Four of the studies were
single-center. The trial duration ranged from 3 to 72months (mean,
18.2 months). Three-ﬁfths of the studies had full score of the Jadad
scale. Supplemental Table 1 describes the baseline characteristics of
patients included in each individual study.
3.3. Direct meta-analysis
Results of meta-analysis based on direct comparisons are pre-
sented in Table 2 and Supplemental Table 2. With regard to post-
operative prophylaxis of endoscopic recurrence, 5-ASA showed no
signiﬁcant difference in efﬁcacy comparedwith placebo (OR¼ 0.69,No. of
patients
Follow-up
(month)
Endoscopic
recurrence
(i2-4)
Severe
endoscopic
recurrence
(i3-4)
Clinical
recurrence
Adverse
events
Jadad
score
69 24 NA NA 12 (17%) 27 (39%) 2
71 20 (28%) 18 (25%)
d 11 12 1 (9%) 0 1 (9%) NA 2
11 4 (36%) 1 (9%) 1 (9%)
44 12 10 (23%) 5 (11%) 7 (16%) 5 (11%) 5
43 18 (42%) 16 (37%) 10 (23%) 3 (7%)
y 55 12 14 (25%) 2 (4%) 3 (5%) 2 (4%) 2
55 29 (53%) 10 (18%) 10 (18%) 0
day
40 12 22 (55%) 6 (15%) 3 (8%) NA 5
41 32 (78%) 8 (20%) 7 (17%)
65 3 22 (34%) 5 (8%) NA 4 (6%) 5
61 24 (39%) 7 (11%) 2 (3%)
47 24 20 (43%) 8 (17%) 24 (51%) 9 (19%) 5
44 28 (64%) 21 (48%) 26 (59%) 6 (14%)
40 26 (65%) 17 (43%) 31 (78%) 4 (10%)
y 42 12 9 (21%) 1 (2%) 2 (5%) 29 (69%) 2
37 9 (24%) 2 (5%) 5 (14%) 26 (70%)
152 18 40 (26%) NA 36 (24%) 8 (5%) 5
166 36 (22%) 50 (30%) 9 (5%)
87 72 NA NA 27 (31%) 7 (8%) 5
76 31 (41%) 10 (13%)
d 11 12 1 (9%) 1 (9%) 0 NA 5
13 11 (85%) 7 (54%) 5 (38%)
y 41 12 18 (44%) 9 (22%) 0 29 (71%) 5
37 23 (62%) 19 (51%) 4 (11%) 13 (35%)
16 24 1 (6%) NA 2 (13%) NA 3
17 11 (65%) 11 (65%)
18 15 (83%) 9 (50%)
31 12 NA NA 3 (10%) NA 5
35 8 (23%)
15 12 3 (20%) NA 2 (13%) NA 3
16 13 (81%) 4 (25%)
, adalimumab.
who could not tolerate metronidazole were switched to ornidazole 1000 mg/day.
salamine of 1.5 g/day postoperatively. However, there was no signiﬁcant difference
Table 2
Direct meta-analysis comparing effects of 5-ASA, IM, biologics and placebo on each outcome.
Comparison Endoscopic recurrence (i2-4) Severe endoscopic recurrence (i3-4) Clinical recurrence Adverse events
No. of studies OR 95% CI No. of studies OR 95% CI No. of studies OR 95% CI No. of studies OR 95% CI
5-ASA vs placebo 5 0.69 0.39e1.20 4 0.46 0.17e1.20 6 0.59 0.43e0.82 6 1.08 0.63e1.85
IM vs placebo 2 0.37 0.20e0.71 2 0.43 0.17e1.09 2 0.33 0.15e0.72 1 2.13 0.60e7.54
Biologics vs placebo 2 0.04 0.01e0.17 1 0.09 0.01e0.88 2 0.25 0.04e1.51 NA
IM vs 5-ASA 4 0.51 0.31e0.84 3 0.25 0.13e0.49 5 0.64 0.35e1.15 4 1.88 1.02e3.48
Biologics vs 5-ASA 1 0.01 0.00e0.14 NA 1 0.14 0.02e0.82 NA
Biologics vs IM 2 0.08 0.01e0.39 1 0.30 0.01e8.32 2 0.21 0.02e2.46 NA
5-ASA, 5-aminosalicylates; IM, Immunomodulators; OR, odds ratio; CI, conﬁdence interval; NA, data not available.
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neity between studies (I2 ¼ 63.2%). Immunomodulators led to a
signiﬁcant reduction of endoscopic recurrence compared with
placebo (OR¼ 0.37, 95% CI 0.20e0.71, P< 0.01) or 5-ASA (OR¼ 0.51,
95% CI 0.31e0.84, P ¼ 0.01). Whatever comparing with placebo
(OR ¼ 0.04, 95% CI 0.01e0.17, P < 0.01), 5-ASA (OR ¼ 0.01, 95% CI
0.00e0.14, P < 0.01) or immunomodulators (OR ¼ 0.08, 95% CI
0.01e0.39, P< 0.01), the use of biologics was associatedwith a large
and signiﬁcant reduction in the risk of endoscopic recurrence.
For severe endoscopic recurrence, 5-ASA (OR ¼ 0.46, 95% CI
0.17e1.20, P ¼ 0.11) and immunomodulators (OR ¼ 0.43, 95% CI
0.17e1.09, P ¼ 0.08) had a trend toward better preventive effect
than placebo without statistical signiﬁcance. Biologics showed
greater efﬁcacy compared with placebo (OR ¼ 0.09, 95% CI 0.01e
0.88, P¼ 0.04), but not with immunomodulators (OR¼ 0.30, 95% CI
0.01e8.32, P ¼ 0.48). The latter led to a signiﬁcant reduction of
severe endoscopic recurrence compared with 5-ASA (OR ¼ 0.25,
95% CI 0.13e0.49, P < 0.01).
In terms of clinical recurrence prevention, 5-ASA (OR ¼ 0.59,
95% CI 0.43e0.82, P < 0.01) and immunomodulators (OR ¼ 0.33,
95% CI 0.15e0.72, P < 0.01) revealed signiﬁcantly superior efﬁcacyFig. 2. Network of comparisons included in analyses. Solid lines represent direct comparison
interventions. (A) outcomedendoscopic recurrence; (B) outcomedsevere endoscopic recurcompared with placebo. Biologics showed non-signiﬁcant disparity
in prophylactic efﬁcacy compared with placebo (OR ¼ 0.25, 95% CI
0.04e1.51, P¼ 0.13) or immunomodulators (OR¼ 0.21, 95% CI 0.02e
2.46, P ¼ 0.22), but signiﬁcantly better efﬁcacy than 5-ASA
(OR ¼ 0.14, 95% CI 0.02e0.82, P ¼ 0.03). There was no signiﬁcant
disparity in reduction of clinical recurrence by using immuno-
modulators compared with 5-ASA (OR ¼ 0.64, 95% CI 0.35e1.15,
P ¼ 0.14).
No signiﬁcant differences in the incidence of adverse events
were found between 5-ASA and placebo groups (OR ¼ 1.08, 95% CI
0.63e1.85, P¼ 0.78), and between immunomodulators and placebo
groups (OR¼ 2.13, 95% CI 0.60e7.54, P¼ 0.24). Immunomodulators
led tomore adverse events comparedwith 5-ASA (OR¼ 1.88, 95% CI
1.02e3.48, P¼ 0.04). There was no study providing data on the side
effect of biologics.
3.4. Network meta-analysis
Fig. 2 shows the network of comparisons for each outcome of
interest, and Table 3 displays the results of network meta-analysis.
Biological treatment was associated with a large and signiﬁcants within randomized controlled trials. Numbers denote trials comparing corresponding
rence; (C) outcomedclinical recurrence; (D) outcomedadverse events.
Table 3
Network meta-analysis comparing effects of 5-ASA, biologics, IM and placebo on
each outcome.
Treatment 5-ASA Biologics IM Placebo
Endoscopic recurrence (i2-4)
5-ASA e e e e
Biologics 30.90 (8.85e129.91) e e e
IM 1.92 (1.05e3.59) 0.06 (0.01e0.21) e e
Placebo 0.70 (0.41e1.13) 0.02 (0.01e0.07) 0.36 (0.18e0.69) e
Severe endoscopic recurrence (i3-4)
5-ASA e e e e
Biologics 17.91 (1.02e732.06) e e e
IM 2.24 (0.60e7.16) 0.13 (0.00e0.24) e e
Placebo 0.56 (0.19e1.57) 0.03 (0.00e0.49) 0.25 (0.07e0.94) e
Clinical recurrence
5-ASA e e e e
Biologics 5.44 (2.03e20.38) e e e
IM 1.64 (1.00e3.04) 0.30 (0.09e0.90) e e
Placebo 0.56 (0.35e0.86) 0.10 (0.03e0.28) 0.34 (0.17e0.61) e
Adverse events
5-ASA e e e e
Biologics e e e e
IM 0.51 (0.26e1.05) e e e
Placebo 1.18 (0.60e2.61) e 2.26 (0.94e6.21) e
5-ASA, 5-aminosalicylates; IM, Immunomodulators.
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with the other agents or placebo. Immunomodulators demon-
strated greater efﬁcacy in terms of endoscopic and clinical recur-
rence prophylaxis compared with 5-ASA or placebo, but with
higher incident rate of adverse events. 5-ASA showed superior
beneﬁt for the prevention of clinical recurrence compared with
placebo, with no increase in the incidence of adverse events.
Fig. 3 summarizes the estimated probability that a given drug
class is the next best one to prevent postoperative CD recurrence, or
to reduce the occurrence of side effect, given available trial data.
Rank 1 is the worst, while rank N is the best. In terms of post-
operative prophylaxis of endoscopic, severe endoscopic and clinical
recurrence, placebo was consistently ranked ﬁrst, followed by 5-
ASA, immunomodulators, and biologics. With regard to the inci-
dence of adverse events, immunomodulators was ranked ﬁrst,
followed by 5-ASA and placebo.4. Discussion
This study demonstrated that mesalamine, immunomodulators,
and biologics were more efﬁcacious than placebo for postoperative
CD prevention. Biological agents were found to be the most effec-
tive medications to prevent CD recurrence after intestinal surgery.
To our knowledge, this is the ﬁrst network meta-analysis in this
evolving area combining direct and indirect comparisons.
Currently, the use of TNF inhibitors as a preventive strategy is
widely recommended for CD patients at high risk of postoperative
recurrence [1,4,5,16]. In general practice, step-up treatment for the
prevention of postoperative CD relapse is still favored by many
doctors on the basis of endoscopic monitoring [6]. We summarized
several risk factors which have been proved as strong predictors for
postoperative recurrence of CD in the included studies
(Supplemental Table 1). It was hard to distinguish the targeted
patients in each trial into high-risk and low-risk classes due to the
limited available data. Only one latest trial clearly emphasized that
the included patients were at high risk if they had two or more risk
factors [21]. Based on their selection criteria, the cohorts in the
majority of the included studies were not at high risk. Data on
smoking status were available in nine studies including 640 pa-
tients, of whom 256 (40%) were current smokers. Data on the status
of previous surgery were also available in nine studies including672 patients, of whom 195 (29%) underwent intestinal resection
previously. The whole mixed cohort in this meta-analysis was able
to be considered as an average-risk population. Because network
meta-analysis that used mixed treatment comparisons for analysis
provided us with a path to achieve a larger sample size [20].
Although clinical recurrence, the appearance of typical disease
symptoms and signs, is the most meaningful outcome measure
[2,7], the deﬁnitions reported in each study were greatly various
(Supplemental Table 1). The Crohn’s Disease Activity Index (CDAI)
was used to measure clinical recurrence in most of the trials,
whereas other simpliﬁed score systems were also applied to this
context. Deﬁnition of endoscopic recurrence was less problematic
due to the universal acceptance of the Rutgeerts scoring system in
all the trials. Moreover, we extracted the data on endoscopic and
severe endoscopic recurrence according to the uniform threshold.
Endoscopy can reveal new epithelial lesions at short term follow-
up after surgery, and the severity of these lesions predicts the
recurrence of clinical symptoms [2,38]. Of CD patients with endo-
scopic recurrence, the majority will develop clinical relapse over
time, with rates approaching 75% by ten years [4,39]. That was why
we chose endoscopic recurrence as the primary endpoint. In the
results of network meta-analysis, the rankings of drug efﬁcacy for
the prevention of endoscopic and clinical recurrence were
completely consistent.
Unfortunately, four studies comparing TNF inhibitors with
others did not provide any available information on the incidence of
adverse events [21,22,35,36]. We were unable to balance the ben-
eﬁts and risks of using biological agents as prophylactic strategy.
However, from another report by Regueiro et al., initiation of
inﬂiximab within four weeks after intestinal operation was not
associated with postoperative complications in CD over the course
of one-year follow-up [40].
A potential heterogeneity across the studies might stem from the
different dosage regimens of one drug class, particularly in mesal-
amine (Supplemental Table 2). Caprilli et al. conducted another
randomized controlled trial, which demonstrated that there was no
disparity in clinically signiﬁcant efﬁcacy between 4.0 g/day and 2.4 g/
day regimen of mesalamine for the prevention of endoscopic and
clinical recurrence at one year of follow-up [24]. One study included
in this meta-analysis by D’Haens et al. compared azathioprine with
placebo for 12 months together with nitroimidazole antibiotics for 3
months in both arms [29]. However, the addition of metronidazole
for 3 months after the surgical treatment to azathioprine was
worthless for the prevention of postsurgical endoscopic recurrence
in a latest randomized trial [25].
Several limitations exist in this study. First, the number of
studies included in this meta-analysis was small that prevented us
from subgroup analysis or sensitivity analysis. Secondly, most of
the trials were short term, generally lasting one-year follow-up.
Thirdly, the limited number of studies with small sample size
comparing biologics with placebo might potentially overestimate
its effect compared with other agents in preventing postoperative
recurrence. However, network meta-analysis seems a reasonable
tool and provides a cost-saving pathway to conduct comparative
effectiveness research with the absence of head-to-head clinical
trials [19,20]. Fourthly, network meta-analysis based on mixed
treatment comparisons may lead to a higher probability of het-
erogeneity among studies. In fact, we used node-split measure to
assess the inconsistency in the mixed treatment comparisons
(Supplemental Table 3). We chose consistency model in the
analysis for each endpoint because all the P values were greater
than 0.05. Finally, we were only able to examine publication bias
in the analysis that compared 5-ASA with placebo and that
compared immunomodulators with 5-ASA. Egger test suggested
the possibility of publication bias in the comparison between 5-
Fig. 3. Ranking of drug efﬁcacy. (A) outcomedendoscopic recurrence; (B) outcomedsevere endoscopic recurrence; (C) outcomedclinical recurrence; (D) outcomedadverse
events.
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unable to deal with this matter due to the small number of
included studies.
In summary, our ﬁndings are provocative enough to stimulate
more hypothesis-driven randomized trials in this ﬁeld. Until addi-
tional data are available, TNF inhibitors should be considered as pri-
oritymedication forprophylaxisofCDrecurrence in thepostoperative
setting. Given the secondary efﬁcacy of immunomodulators and 5-ASA, it is worth exploring the role of sequential or combination
treatment compared with mono-therapy of biologics.Ethical approval
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